Multi-omics Analysis of Coronary Sinus Blood at Reperfusion to Characterize Donor Heart Metabolism and Early Graft Injury
Presented During:
Monday, May 4, 2026: 9:00AM - 4:00PM
McCormick Place Lakeside Center
Posted Room Name:
Exhibit Hall, Poster Area
Abstract No:
P0141
Submission Type:
C. Walton Lillehei Resident Forum
Authors:
Elizabeth Bashian (1), Sariah Hyacinth (2), Nicholas Teman (3), Michael Cain (4), Benjamin Kopecky (2)
Institutions:
(1) University of Colorado Anschutz Medical Center, Aurora, CO, (2) University of Colorado Anschutz Medical Campus, Aurora, CO, (3) University of Colorado School of Medicine, CO, (4) University of Colorado Hospital, Denver, CO
Submitting Author:
Elizabeth Bashian
-
Contact Me
University of Colorado Anschutz Medical Center
University of Colorado Anschutz Medical Center
Co-Author(s):
Sariah Hyacinth
-
Contact Me
University of Colorado Anschutz Medical Campus
University of Colorado Anschutz Medical Campus
*Nicholas Teman
-
Contact Me
University of Colorado School of Medicine
University of Colorado School of Medicine
Michael Cain
-
Contact Me
University of Colorado Hospital
University of Colorado Hospital
Benjamin Kopecky
-
Contact Me
University of Colorado Anschutz Medical Campus
University of Colorado Anschutz Medical Campus
Presenting Author:
Elizabeth Bashian
-
Contact Me
University of Colorado Anschutz Medical Center
University of Colorado Anschutz Medical Center
Abstract:
Background: Metabolomics characterizes myocardial metabolism and reveals shifts linked to ischemia-reperfusion injury into donor heart recovery. This study compares metabolic signatures between DCD and DBD hearts recovered with normothermic regional perfusion (NRP) vs ex-vivo machine perfusion (EVMP).
Methods: Adult heart transplant recipients undergoing either DBD or DCD transplantation were enrolled. Coronary sinus blood (CSB) was collected to capture metabolites reflective of myocardial metabolism at time of graft implantation. Samplels were processed using standardized protocols and analyzed by institutional metabolomics and lipidomics core using mass-spectrometry based profiling. DCD samples were further stratified by NRP vs EVMP. Data were pre-processed, normalized, and analyzed using partial least-squares discriminant analysis (PLS-DA) to assess clustering by donor type and recovery method. Variable importance in projection (VIP) scores identified key metabolites and lipid species contributing to group discrimination.
Results: 29 CSB samples were analyzed (16 DCD, 13 DBD). Among 9 DCD donors, there were 9 NRP and 7 EVMP donors. PLS-DA demonstrated clear metabolic separation between DCD and DBD profiles in metabolomics and lipidomics datasets. Variable importance in projection (VIP) scores identified key metabolites driving this distinction. Compared with DBD grafts, DCD grafts showed lower levels of included D-arabitiol/xylitol/ribitol (DC 0.54, p<0.01), L-glutamine (FC 0.67, p<0.01), thymidine (FC 0.48, p<0.01), L-arginine (FC 0.55, p=0.006), markers linked to energy metabolism, cellular repair, and nitric oxide synthesis. DCD grafts also showed higher levels of mannitol/sorbitol/glucitol/iditol (FC 12.53, p<0.01), associated with oxidative stress during reperfusion.
Lipidomic analysis revealed significant changes in triglycerides and fatty acid species, including TG(22:1_16:0_18:0) (FC 0.42, p<0.05) and FA(20:1)(FC 1.51, p<0.05).
Within the DCD cohort, multivariate modeling with PLS-DA showed distinct clustering between NRP and EVMP grafts. Discriminatory metabolites included D-rhamnose (FC 0.012, p<0.001) and DG(P-6:0_16:0) (FC 0.35, p<0.001), reflecting divergent reperfusion metabolism between groups.
Conclusion: Distinct metabolomic and lipidomic profiles were observed in DCD compared to DBD, and NRP vs EVMP. Metabolic profiling at time of reperfusion may enable identification of at-risk grafts and guide optimization of recovery.
Methods: Adult heart transplant recipients undergoing either DBD or DCD transplantation were enrolled. Coronary sinus blood (CSB) was collected to capture metabolites reflective of myocardial metabolism at time of graft implantation. Samplels were processed using standardized protocols and analyzed by institutional metabolomics and lipidomics core using mass-spectrometry based profiling. DCD samples were further stratified by NRP vs EVMP. Data were pre-processed, normalized, and analyzed using partial least-squares discriminant analysis (PLS-DA) to assess clustering by donor type and recovery method. Variable importance in projection (VIP) scores identified key metabolites and lipid species contributing to group discrimination.
Results: 29 CSB samples were analyzed (16 DCD, 13 DBD). Among 9 DCD donors, there were 9 NRP and 7 EVMP donors. PLS-DA demonstrated clear metabolic separation between DCD and DBD profiles in metabolomics and lipidomics datasets. Variable importance in projection (VIP) scores identified key metabolites driving this distinction. Compared with DBD grafts, DCD grafts showed lower levels of included D-arabitiol/xylitol/ribitol (DC 0.54, p<0.01), L-glutamine (FC 0.67, p<0.01), thymidine (FC 0.48, p<0.01), L-arginine (FC 0.55, p=0.006), markers linked to energy metabolism, cellular repair, and nitric oxide synthesis. DCD grafts also showed higher levels of mannitol/sorbitol/glucitol/iditol (FC 12.53, p<0.01), associated with oxidative stress during reperfusion.
Lipidomic analysis revealed significant changes in triglycerides and fatty acid species, including TG(22:1_16:0_18:0) (FC 0.42, p<0.05) and FA(20:1)(FC 1.51, p<0.05).
Within the DCD cohort, multivariate modeling with PLS-DA showed distinct clustering between NRP and EVMP grafts. Discriminatory metabolites included D-rhamnose (FC 0.012, p<0.001) and DG(P-6:0_16:0) (FC 0.35, p<0.001), reflecting divergent reperfusion metabolism between groups.
Conclusion: Distinct metabolomic and lipidomic profiles were observed in DCD compared to DBD, and NRP vs EVMP. Metabolic profiling at time of reperfusion may enable identification of at-risk grafts and guide optimization of recovery.
Category:
Adult Cardiac
Image or Table
